This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Validity of estimate of measure of effectiveness
The study was a retrospective single-centre cohort study. The internal validity of the effectiveness results cannot reasonably be guaranteed, given the retrospective nature of the study design and the non-randomisation of patients in each group. Further, the study groups were not comparable in terms of preoperative risk factors such as hypertension, tobacco use and hyperlipidaemia. However, the authors adjusted for baseline differences between the two groups and tried to account for such differences. The outcome assessment was not reported to be blinded, which can potentially introduce bias into the study results. In addition, since no power calculations were reported, the study might have had insufficient power to detect statistical differences in rates of mortality, stroke or myocardial infarction. The study sample seems to have been representative of the study population since all consecutive patients (other than those with lesions caused by either inflammatory arteritides or radiation exposure) who underwent either intervention were reviewed, and no refusal to participate was reported.
Validity of estimate of measure of benefit
The authors did not derive a measure of health benefit. See the comments in the 'Validity of estimate of measure of effectiveness' field (above).
Validity of estimate of costs
There was very limited information on the actual costs collected. Therefore, it was unclear whether all the relevant costs were included in the analysis. In addition, the study perspective was not stated, though it appears to have been that of the hospital. The analysis included short-term in-hospital charges that were used as cost proxies without any adjustment. The use of charges to proxy costs may limit the generalisability of the study results. The exclusion of surgeons' fees might affect the study results. The costs were estimated in a sub-sample of the study patients, but it was unclear if the sub-sample was composed of consecutive patients. The quantities and the costs were not analysed nor reported separately, thus limiting the reproducibility of the study in other settings. No statistical analysis was performed on the cost or quantity data. Discounting was appropriately not carried out as the cost time horizon was short term. The price year was not reported, thus impeding any future reflation exercises.
Other issues
In view of the retrospective nature of the study design, its methodological drawbacks and the lack of a sensitivity analysis, some degree of caution may be required in the interpretation of the study results. The authors compared their findings with those from other studies and found them, in general, to be concordant. The authors did not address the issue of generalisability of the results to other settings. They do not appear to have presented their results selectively. The study involved patients treated for symptomatic atherosclerotic single-vessel BC disease and this was reflected in the authors' conclusions. The authors' conclusions reflected the scope of the analysis. The authors did not report any limitations to their study.
Implications of the study
Long-term data about endovascular procedures are still needed to compare both strategies in terms of their long-term durability, patterns of failure, efficacy as an adjunct to coronary artery bypass grafting, need for anticoagulation, efficacy as treatment for complex (multi-vessel) disease, and long-term cost. Until these additional questions are answered, the precise indications for endovascular intervention versus operative reconstruction for the treatment of BC disease remain unsettled.
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